TOP STORIES

• BUSINESS Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
  February 17, 2026

• BUSINESS Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
  February 17, 2026

• REGULATORY 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
  February 17, 2026

• REGULATORY MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
  February 17, 2026

• REGULATORY Japan Panel to Review Sumitomo, Cuorips iPSC Products on Feb. 19
  February 16, 2026

• REGULATORY DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
  February 13, 2026

• BUSINESS FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
  February 13, 2026

• BUSINESS Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
  February 12, 2026

• BUSINESS Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
  February 10, 2026

• REGULATORY LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
  February 9, 2026

• COMMENTARY Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
  February 9, 2026

• ORGANIZATION Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
  February 6, 2026

• BUSINESS Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
  February 6, 2026

• BUSINESS Ono Recalls Certain Opdivo Lots over Possible Metal Contamination
  February 6, 2026

• COMMENTARY Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
  February 5, 2026

• BUSINESS Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
  February 4, 2026

• BUSINESS Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
  February 4, 2026

• ORGANIZATION FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
  February 3, 2026

• BUSINESS AstraZeneca Names Andy Barnett as New Japan President
  February 3, 2026

• BUSINESS Fuji Says Eylea Biosimilar Patent Risk Cleared under Global Settlement
  February 2, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »